LifePearl-Doxo Pharmacokinetic (PK) Study

Inclusion Criteria: * Patient is at least 18 years old * HCC diagnosed according to updated American Association for the Study of Liver Diseases (AASLD) or EASL-European Organization for Research and Treatment of Cancer (EORTC) criteria * BCLC B patients or BCLC A patients not candidates for curative treatment (resection, transplantation, ablation) or who have failed/recurred after resection/ablation * Tumor burden (located in one or two lobes) that can be sufficiently and selectively embolized with required dose of LifePearl loaded with doxorubicin * Performance status (PS) 0 * Normal liver or compensated cirrhosis with preserved liver function (Child-Pugh A, score ≤ 6 points) without ascites in the absence of diuretic treatment * Total bilirubin ≤2.0 mg/dl * Adequate renal function (serum creatinine \< 1.5 X ULN) * Patient has provided written informed consent * Patient is affiliated to social security or equivalent system (France only) Exclusion Criteria: * Patient previously treated with any intra-arterial therapy for HCC or sorafenib * Eligible for curative treatment (resection/radiofrequency ablation (RFA), transplantation therapies); * Advanced liver disease: Child-Pugh's B-C class or active gastrointestinal bleeding, encephalopathy. Bilirubin levels \>2.0 mg/dl; * Advanced tumoral disease: BCLC class C (vascular invasion -even segmental, extra-hepatic spread or cancer-related symptoms=PS of 1-2) or D class (WHO performance status 3 or 4) * Patient with another primary tumor * Patient with refractory ascites or on diuretic treatment * Patient with history of biliary tree disease or biliary dilatation * Portal vein thrombosis, porto-systemic shunt, hepatofugal blood flow or absent portal blood flow in the liver area to be treated * Contraindication to multiphasic CT and MRI (e.g. allergy to contrast media); * Any other contraindication for embolization or local doxorubicine treatment; * Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints * In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study * Pregnant or breast-feeding women * Patient is under judicial protection (France only)